Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Notable: China National Study of Adrenal Venous Sampling Primary completion pushed from Dec 30, 2026 to Aug 31, 2028
- Notable: Thermoses as a Way to Provide Human Milk to Toddlers in Daycare Primary completion pushed from Nov 2026 to Nov 2027
- Notable: Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia · Hepatocellular Carcinoma Primary completion pushed from Nov 22, 2025 to Nov 22, 2027
- Notable: Stratified, Multi-ARm, muLti-site Randomised Platform Trial Aiming to Reduce the INcidence of Post-operative SSI Primary completion pushed from Aug 31, 2026 to Mar 31, 2027
- Notable: Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas Primary and study completion pushed from Aug 31, 2026 to Aug 31, 2028
- Notable: NEPTUNE Match Study Primary and study completion pushed from Dec 30, 2029 to Dec 30, 2030
- Notable: Mechanisms of Resistance Exercise Training for Improved Muscle Insulin Sensitivity Primary completion pushed from Aug 31, 2028 to Sep 1, 2029
- Notable: Continuous Supraglottic Oxygen Insufflation Via Video Laryngoscope Blade on Apneic Oxygenation During Tracheal Intubation Under General Anesthesia Primary completion pushed from Jun 22, 2026 to Jul 1, 2029
- Notable: KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT) Recruitment opened
- Notable: Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) Recruitment opened
- Notable: Oral VK2735 for Weight Management · Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) Recruitment opened
- Notable: ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular Recruitment opened
- Notable: GFH276 · RAS-Mutant Advanced Solid Tumors Recruitment opened
- Notable: BBM-C101 Injection · Cervical High-Grade Squamous Intraepithelial Lesion(HSIL) Recruitment opened
- Notable: RO7821657 · Solid Tumors Recruitment opened
- Notable: Mass Balance Study of [¹⁴C]Purinostat Mesylate for Injection in Healthy Participants Recruitment opened
- Notable: Post Market Study of the Flexagon Only System and Flexagon Plus OTOLoc for Creation of Side-to-Side Duodeno-Ileal Diversion & Flexagon Plus OTOLoc Self Forming Magnet (SFM) System for Creation of Side-to-Side Jejunum-Jejunum and Ileal-Ileal Anastomoses Recruitment opened
- Notable: GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study Recruitment opened
- Notable: Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy Recruitment opened
- Notable: Decision Counseling and Follow-up for Shield+ Patients Recruitment opened
- Notable: First-Line Lenvatinib in Child-Pugh B · HCC Unsuitable for Curative Treatment Recruitment opened
- Notable: Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast Recruitment opened
- Notable: PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study Recruitment opened
- Notable: Targeting Lifestyle to Improve Colorectal Cancer Screening Recruitment opened
- Notable: Povidone Iodine for Caries Prevention Enrolling by invitation only
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates